Trial Profile
A Phase I/II Study of LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 31 May 2023
Price :
$35
*
At a glance
- Drugs IMC CS4 (Primary) ; Cobimetinib; Vemurafenib
- Indications Malignant melanoma
- Focus Therapeutic Use
- 29 May 2023 Status changed from active, no longer recruiting to discontinued according to results published in the Investigational New Drugs.
- 29 May 2023 Results published in the Investigational New Drugs
- 26 Jul 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Dec 2022.